261 related articles for article (PubMed ID: 37442619)
1. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
[TBL] [Abstract][Full Text] [Related]
2. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
4. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
Zhang N; Wei L; Ye M; Kang C; You H
Front Immunol; 2020; 11():592612. PubMed ID: 33329578
[TBL] [Abstract][Full Text] [Related]
5. Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Omuro A
Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):266-269. PubMed ID: 35976319
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
7. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
9. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
10. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Carter TC; Medina-Flores R; Lawler BE
Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
[TBL] [Abstract][Full Text] [Related]
12. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
13. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR
Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Wu S; Calero-Pérez P; Arús C; Candiota AP
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
[TBL] [Abstract][Full Text] [Related]
15. Management of glioblastoma: State of the art and future directions.
Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
[TBL] [Abstract][Full Text] [Related]
16. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Neagu MR; Reardon DA
Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
[TBL] [Abstract][Full Text] [Related]
17. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
18. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
Sanders S; Debinski W
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096
[TBL] [Abstract][Full Text] [Related]
19. Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma.
Meng L; Wang C; Lu Y; Sheng G; Yang L; Wu Z; Xu H; Han C; Lu Y; Han F
ACS Appl Mater Interfaces; 2021 Mar; 13(10):11657-11671. PubMed ID: 33684289
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]